MYOMO, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that MYOMO, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Aug 16, 2022 | $1.00B | Mar 13, 2023 |
| FY2018 | Dec 31, 2018 | $2.44M | Mar 12, 2019 |
| FY2018 | Dec 31, 2017 | $1.56M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.10M | Mar 12, 2018 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.93M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $32.55M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $19.24M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $15.56M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $13.86M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $7.58M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $3.84M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $2.44M | Mar 13, 2020 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $26.89M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $23.19M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $13.18M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $10.25M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $10.31M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $4.98M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $2.42M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $1.72M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.05M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $821.1K | Mar 12, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($15.57M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($6.18M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($8.15M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($10.72M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($10.37M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($11.56M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($10.71M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($10.32M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($12.10M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($3.62M) | Mar 12, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.40M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($6.21M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($8.23M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($10.67M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($10.27M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($10.50M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($10.80M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($10.53M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.55M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($3.28M) | Mar 12, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.94M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $4.77M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $2.64M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $2.48M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $2.56M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $1.67M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.75M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $1.84M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.75M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.12M | Mar 12, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $18.78M | Mar 8, 2024 |
| FY2023 | Dec 31, 2022 | $18.44M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $18.02M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $13.82M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $11.46M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $10.41M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $5.85M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $2.98M | Mar 12, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.51M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($3.29M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($6.17M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($10.23M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($9.55M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($9.03M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($10.34M) | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | ($9.61M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($6.15M) | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | ($3.20M) | Mar 12, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.74M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $1.36M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $145.8K | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $111.8K | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $326.5K | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $45.8K | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $52.0K | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $126.9K | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $67.0K | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.9K | Mar 12, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $38.64M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $42.24M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $14.58M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $10.16M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $20.10M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $14.71M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $6.60M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $8.28M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $13.97M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $1.66M | Mar 12, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $27.23M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $17.53M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $5.59M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $3.80M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $4.69M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $3.14M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.77M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $1.86M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.53M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $6.52M | Mar 12, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.40M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $24.71M | Mar 9, 2026 |
| FY2025 | Dec 31, 2023 | $8.99M | Mar 9, 2026 |
| FY2024 | Dec 31, 2022 | $6.36M | Mar 10, 2025 |
| FY2023 | Dec 31, 2021 | $15.41M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | $11.57M | Mar 13, 2023 |
| FY2021 | Dec 31, 2019 | $6.43M | Mar 11, 2022 |
| FY2020 | Dec 31, 2018 | $6.43M | Mar 10, 2021 |
| FY2019 | Dec 31, 2017 | $12.45M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | ($17.53M) | Mar 12, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($118.69M) | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | ($103.11M) | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | ($96.93M) | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | ($88.78M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($78.06M) | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | ($67.69M) | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | ($56.13M) | Mar 10, 2021 |
| FY2019 | Jan 1, 2019 | ($45.41M) | Mar 13, 2020 |
| FY2019 | Dec 31, 2018 | ($45.29M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($34.97M) | Mar 12, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.13M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $24.37M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | $6.87M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | $5.35M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $15.52M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | $12.24M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | $4.47M | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | $6.54M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $12.96M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | $797.2K | Mar 12, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.22M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Mar 9, 2026 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 13, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | (1) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 13, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 38.47M | Mar 9, 2026 |
| FY2025 | Dec 31, 2024 | 34.38M | Mar 9, 2026 |
| FY2024 | Dec 31, 2023 | 27.14M | Mar 10, 2025 |
| FY2023 | Dec 31, 2022 | 7.75M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 6.87M | Mar 13, 2023 |
| FY2021 | Dec 31, 2020 | 4.59M | Mar 11, 2022 |
| FY2020 | Dec 31, 2019 | 574,497 | Mar 10, 2021 |
| FY2019 | Dec 31, 2018 | 414,979 | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 11.14M | Mar 12, 2019 |
| FY2017 | Dec 31, 2016 | 1.12M | Mar 12, 2018 |